Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
Peptide
Gastrin-Releasing Peptide Receptor (GRPR) aka BB2 Receptor)
Protein
N/A nM (reported value)
Peptide binding assays: Phosphate-buffered saline (PBS) with 1% fetal calf serum (FCS).
RT°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Binds to and is taken up by MDA-MB 231 breast cancer cells.
Negative controls were normal mammary epithelial cells and human blood monocytes. Aptamer was conjugated to survivin siRNA through the terminal cysteine residue, which was successfully delivered to MDA-MB 231 cells.
Gastrin-Releasing Peptide (GRP-1) (ID# 386)
Negative controls were normal mammary epithelial cells and human blood monocytes. Aptamer was conjugated to survivin siRNA through the terminal cysteine residue, which was successfully delivered to MDA-MB 231 cells.
36
1417.7 g/mole
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
M Sioud et al. Efficient siRNA targeted delivery into cancer cells by gastrin-releasing peptides. Bioconjugate Chem 23(2012): 1040-1049.
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.